BioSpace News Archive

BioMidwest

New American Academy of Dermatology Survey Shows Most Americans Are Not Concerned About Skin Cancer, Even if They Are at Risk

As an African American female, Ilia Smith didn’t think she would get melanoma. However, after years of tanning and being outdoors, her life changed drastically when she was diagnosed with stage 2 melanoma.

April 25, 2023

·

4 min read

Business

Pixium Vision announces the availability of its annual report for the financial year 2022

Pixium Vision SA announces that its annual report for the year 2022 has been made available on the Company’s website.

April 25, 2023

·

1 min read

Business

Break Through Cancer, A New Research Consortium, Names First Class of Scientists Designated as Catalysts for Innovation and Collaboration

Break Through Cancer, a foundation designed to find new solutions to some of the most intractable challenges in cancer, has named four individuals as Break Through Cancer Scientists—Neelkanth Bardhan, Sreyashi Basu, Paola A. Guerrero, and Thomas R. Pisanic II.

April 25, 2023

·

4 min read

Pharm Country

Intelivation Technologies Announces Center of Excellence Grand Opening

Intelivation Technologies announced the official opening of their Center of Excellence – a state-of-the-art research and development facility devoted to advancing orthopedic technologies in the life sciences sector.

April 25, 2023

·

1 min read

Genetown

Akebia Receives European Commission Approval for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis

Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that the European Commission (EC) has granted marketing authorisation for Vafseo™ (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.

April 25, 2023

·

6 min read

FDA

FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved QALSODY™ (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene.

April 25, 2023

·

16 min read

Business

Kaiser Permanente names Nari Gopala as chief digital officer

Kaiser Permanente announced that Narayanan “Nari” Gopala has been promoted to chief digital officer for Kaiser Foundation Health Plan and Hospitals.

April 25, 2023

·

2 min read

FDA

Muscular Dystrophy Association Celebrates FDA Approval of Biogen’s Qalsody for Treatment of SOD1-ALS

The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) accelerated approval of Qalsody (tofersen), for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease) associated with mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS).

April 25, 2023

·

5 min read

Galapagos’ shareholders approve all resolutions proposed by the Board of Directors at the annual shareholders’ meeting

Galapagos NV announces the approval of all resolutions proposed at its annual shareholders’ meeting held today at 14.00 CET.

April 25, 2023

·

1 min read

Business

RxSight, Inc. to Report First Quarter Financial Results on May 9, 2023

RxSight, Inc. announced that it will report financial results for the first quarter 2023 after the market close on Tuesday, May 9, 2023.

April 25, 2023

·

1 min read